Ferring Pharmaceuticals today announced positive results across all five of its prospective trials for a live biotherapeutic designed to reduce recurrent C. difficile infection (rCDI).
The therapy is being developed to decrease C. difficile (C. diff) infection recurrences.
Biopharma companies strengthen their senior leadership teams and boards of directors with this week’s appointments.
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress.
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection.
Ferring Pharmaceuticals and Rebiotix today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides difficile (C. difficile) infection, as part of IDWeek 2021.
Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile (C. difficile) infection, adding to robust evidence of largest clinical development program in microbiome-based therapeutics
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile infection will be presented as part of an invited talk at Digestive Disease Week® 2021.
The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this patient community and help more people build families
Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile (C. diff) infection These data presentations strengthen the company’s leadership and scientific and clinical understanding of the two investigational therapeutics
Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, Dr. Ken Blount, has been appointed to Karolinska Institutet’s Joint Steering Committee (JSC) of the Centre for Translation Microbiome Research (CTMR) in Stockholm, Sweden.
The fourth annual summit will take place on June 26-28 in Boston, MA.